## Nishida Naoshi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6755519/publications.pdf

Version: 2024-02-01

201575 175177 2,931 71 27 52 h-index citations g-index papers 72 72 72 3718 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma. Hepatology, 2008, 47, 908-918.	3.6	250
2	Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study. Cancers, 2019, 11, 1084.	1.7	200
3	Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer, 2015, 4, 253-262.	4.2	172
4	Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria). Digestive Diseases, 2015, 33, 751-758.	0.8	167
5	Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma: A Systematic Review. Current Genomics, 2011, 12, 130-137.	0.7	165
6	Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology, 2012, 56, 994-1003.	3.6	129
7	Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia. Clinical Cancer Research, 2015, 21, 4234-4242.	3.2	128
8	Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study. Cancers, 2019, 11, 952.	1.7	114
9	Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication. Oncology, 2017, 92, 40-49.	0.9	100
10	Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma. Digestive Diseases, 2015, 33, 771-779.	0.8	76
11	High copy amplification of the aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biology and Therapy, 2007, 6, 525-533.	1.5	75
12	Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. Hepatology Research, 2018, 48, 622-634.	1.8	58
13	Extensive Methylation Is Associated with $\hat{l}^2$ -Catenin Mutations in Hepatocellular Carcinoma: Evidence for Two Distinct Pathways of Human Hepatocarcinogenesis. Cancer Research, 2007, 67, 4586-4594.	0.4	57
14	Recent Advancements in Comprehensive Genetic Analyses for Human Hepatocellular Carcinoma. Oncology, 2013, 84, 93-97.	0.9	56
15	Oncogenic Signal and Tumor Microenvironment in Hepatocellular Carcinoma. Oncology, 2017, 93, 160-164.	0.9	56
16	Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. Liver Cancer, 2021, 10, 380-393.	4.2	51
17	MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma. Liver Cancer, 2017, 6, 113-125.	4.2	50
18	Unique features associated with hepatic oxidative DNA damage and DNA methylation in nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1646-1653.	1.4	49

#	Article	IF	Citations
19	Rescue EUS-guided intrahepatic biliary drainage for malignant hilar biliary stricture after failed transpapillary re-intervention. Surgical Endoscopy and Other Interventional Techniques, 2017, 31, 4764-4772.	1.3	40
20	Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2. Digestive Diseases, 2017, 35, 589-597.	0.8	40
21	Gankyrin induces <scp>STAT</scp> 3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma. Cancer Science, 2017, 108, 1996-2003.	1.7	40
22	Alteration of Epigenetic Profile in Human Hepatocellular Carcinoma and Its Clinical Implications. Liver Cancer, 2014, 3, 417-427.	4.2	38
23	Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PDâ°'1/PD-L1 Checkpoint Blockade. Cancers, 2020, 12, 3048.	1.7	37
24	Comprehensive allelotyping of well-differentiated human hepatocellular carcinoma with semiquantitative determination of chromosomal gain or loss. Genes Chromosomes and Cancer, 2002, 35, 329-339.	1.5	36
25	Liver damage related to immune checkpoint inhibitors. Hepatology International, 2019, 13, 248-252.	1.9	36
26	Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 583-592.	4.2	33
27	Unique Association between Global DNA Hypomethylation and Chromosomal Alterations in Human Hepatocellular Carcinoma. PLoS ONE, 2013, 8, e72312.	1.1	31
28	Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma. Oncology, 2015, 89, 47-52.	0.9	31
29	Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 615-628.	4.2	31
30	Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B. Journal of Medical Virology, 2019, 91, 1804-1810.	2.5	28
31	Alteration of the p14 ARF gene and p53 status in human hepatocellular carcinomas. Journal of Gastroenterology, 2004, 39, 355-361.	2.3	27
32	Discrete breakpoint mapping and shortest region of overlap of chromosome arm 1q gain and 1p loss in human hepatocellular carcinoma detected by semiquantitative microsatellite analysis. Genes Chromosomes and Cancer, 2005, 42, 34-43.	1.5	27
33	Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. Cancers, 2020, 12, 1274.	1.7	27
34	Association between Genetic and Immunological Background of Hepatocellular Carcinoma and Expression of Programmed Cell Death-1. Liver Cancer, 2020, 9, 426-439.	4.2	26
35	Genome-Wide Profiling of DNA Methylation and Tumor Progression in Human Hepatocellular Carcinoma. Digestive Diseases, 2014, 32, 658-663.	0.8	25
36	Role of Oncogenic Pathways on the Cancer Immunosuppressive Microenvironment and Its Clinical Implications in Hepatocellular Carcinoma. Cancers, 2021, 13, 3666.	1.7	25

3

#	Article	lF	CITATIONS
37	Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy. Cancers, 2018, 10, 367.	1.7	24
38	Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology. Hepatology International, 2019, 13, 416-421.	1.9	24
39	Serum Levels of α-Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2021, 19, 162-170.e4.	2.4	24
40	Prognostic Impact of Multiple Allelic Losses on Metastatic Recurrence in Hepatocellular Carcinoma after Curative Resection. Oncology, 2002, 62, 141-148.	0.9	22
41	Artificial Intelligence in Medical Imaging and Its Application in Sonography for the Management of Liver Tumor. Frontiers in Oncology, 2020, 10, 594580.	1.3	21
42	Clinical Significance of the Duality of Wnt/ $\hat{l}^2$ -Catenin Signaling in Human Hepatocellular Carcinoma. Cancers, 2022, 14, 444.	1.7	20
43	Impact of peginterferon alphaâ€2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B. Journal of Medical Virology, 2013, 85, 987-995.	2.5	19
44	Artificial intelligence (AI) models for the ultrasonographicÂdiagnosis of liver tumors and comparison of diagnostic accuracies between AI and human experts. Journal of Gastroenterology, 2022, 57, 309-321.	2.3	19
45	Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies. Clinical Cancer Research, 2022, 28, 3443-3451.	3.2	19
46	Efficacy of a modified double-guidewire technique using an uneven double lumen cannula (uneven) Tj ETQq0 0 C Endoscopy and Other Interventional Techniques, 2020, 34, 1432-1441.	) rgBT /Ove 1.3	erlock 10 Tf 5 18
47	Clinical Significance of Epigenetic Alterations in Human Hepatocellular Carcinoma and Its Association with Genetic Mutations. Digestive Diseases, 2016, 34, 708-713.	0.8	17
48	Computer aided diagnosis system developed for ultrasound diagnosis of liver lesions using deep learning., 2019,,.		15
49	Identification of Epigenetically Inactivated Genes in Human Hepatocellular Carcinoma by Integrative Analyses of Methylation Profiling and Pharmacological Unmasking. Digestive Diseases, 2014, 32, 740-746.	0.8	12
50	Long-term prognosis and management of hepatocellular carcinoma after curative treatment. Clinical and Molecular Hepatology, 2020, 26, 480-483.	4.5	12
51	Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma. Digestive Diseases, 2017, 35, 618-622.	0.8	10
52	Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms. Digestive Endoscopy, 2018, 30, 659-666.	1.3	10
53	Value of artificial intelligence with novel tumor tracking technology in the diagnosis of gastric submucosal tumors by contrastâ€enhanced harmonic endoscopic ultrasonography. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 841-846.	1.4	10
54	Gender Differences in the Livers of Patients with Hepatocellular Carcinoma and Chronic Hepatitis C Infection. Digestive Diseases, 2012, 30, 547-553.	0.8	9

#	Article	IF	Citations
55	Hepatic DNA Methylation Is Affected by Hepatocellular Carcinoma Risk in Patients with and without Hepatitis Virus. Digestive Diseases, 2015, 33, 745-750.	0.8	9
56	Impaired expression of ATPâ€binding cassette transporter G2 and liver damage in erythropoietic protoporphyria. Hepatology, 2015, 62, 1638-1639.	3.6	9
57	Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease. Scientific Reports, 2021, 11, 9242.	1.6	9
58	Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2. Digestive Diseases, 2017, 35, 583-588.	0.8	7
59	Optimal cropping for input images used in a convolutional neural network for ultrasonic diagnosis of liver tumors. Japanese Journal of Applied Physics, 2020, 59, SKKE09.	0.8	6
60	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. Journal of Histochemistry and Cytochemistry, 2022, 70, 53-81.	1.3	6
61	Accumulation of Genetic and Epigenetic Alterations in the Background Liver and Emergence of Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease. Cells, 2021, 10, 3257.	1.8	6
62	Monoethanolamine Oleate Sclerotherapy for Polycystic Liver Disease. Digestive Diseases, 2016, 34, 654-658.	0.8	5
63	Stress Response Protein RBM3 Promotes the Development of Colitis-associated Cancer. Inflammatory Bowel Diseases, 2017, 23, 66-74.	0.9	5
64	Clinical implications of the dual blockade of the PD-1/PD-L1 and vascular endothelial growth factor axes in the treatment of hepatocellular carcinoma. Hepatobiliary Surgery and Nutrition, 2020, 9, 640-643.	0.7	5
65	Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria. Scientific Reports, 2022, 12, 6100.	1.6	4
66	Contribution of C1485T mutation in the HBx gene to human and murine hepatocarcinogenesis. Scientific Reports, 2017, 7, 10440.	1.6	3
67	Deep-learning framework based on a large ultrasound image database to realize computer-aided diagnosis for liver and breast tumors. , 2021, , .		3
68	Usefulness of the Novel Snare-over-the-Guidewire Method for Transpapillary Plastic Stent Replacement (with Video). Journal of Clinical Medicine, 2021, 10, 2858.	1.0	2
69	Improved Tumor Response to Lenvatinib Re-Treatment after Failure of Immune Checkpoint Inhibitors in a Patient with Advanced Hepatocellular Carcinoma. Liver Cancer, 2021, 10, 535-538.	4.2	2
70	Cystic duct antegrade stenting for cholangitis after the long-term deployment of lumen-apposing metal stents for calculous cholecystitis. Endoscopic Ultrasound, 2018, 7, 349.	0.6	1
71	Should Contrast-Enhanced Harmonic Endoscopic Ultrasound Be Incorporated into the International Consensus Guidelines to Determine the Appropriate Treatment of Intraductal Papillary Mucinous Neoplasm?. Journal of Clinical Medicine, 2021, 10, 1818.	1.0	0